US 11,814,367 B2
Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
David John Morgans, Jr., Los Altos, CA (US); Kevin Mellem, Redwood City, CA (US); Hannah L. Powers, San Diego, CA (US); Patrick Sang Tae Lee, Walnut Creek, CA (US); Walter Won, San Diego, CA (US); and Christopher Joseph Sinz, Walnut Creek, CA (US)
Assigned to MAZE THERAPEUTICS, INC., South San Francisco, CA (US)
Filed by Maze Therapeutics, Inc., South San Francisco, CA (US)
Filed on Mar. 14, 2022, as Appl. No. 17/694,311.
Claims priority of provisional application 63/266,572, filed on Jan. 9, 2022.
Claims priority of provisional application 63/161,347, filed on Mar. 15, 2021.
Prior Publication US 2023/0104740 A1, Apr. 6, 2023
Int. Cl. C07D 403/12 (2006.01); C07D 207/16 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 405/06 (2006.01); C07D 413/06 (2006.01); C07D 413/14 (2006.01); C07D 417/06 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/10 (2006.01); C07D 491/048 (2006.01); C07D 491/08 (2006.01); C07D 498/10 (2006.01)
CPC C07D 403/12 (2013.01) [C07D 207/16 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 413/06 (2013.01); C07D 413/14 (2013.01); C07D 417/06 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 491/048 (2013.01); C07D 491/08 (2013.01); C07D 498/10 (2013.01)] 41 Claims
OG exemplary drawing
 
1. A compound of formula (I-A):

OG Complex Work Unit Chemistry
or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:
Y1 is CH or N;
Rx and Rz are independently H, halo, C1-6alkyl, or —NH2, wherein, when Y1 is CH, the C1-6alkyl of Rx or Rz may be optionally substituted with one or more halo;
Ry is (i) C1-6alkyl, or (ii) C3-10cycloalkyl, wherein the C3-10cycloalkyl is optionally substituted with one or more halo or C1-6alkyl;
Rk is H, halo, —OH, —NH2, or —NH—C(O)C1-6alkyl:
R2 is C1-6alkyl, wherein the C1-6alkyl of R2 is substituted with one or more Ra, wherein Ra is —OH or 5-20 membered heteroaryl, wherein the 5-20 membered heteroaryl of Ra is optionally substituted with one or more Rb; and
Rb is halo, C1-6alkyl, C1-6alkoxy, —NH2, —NH(C1-6alkyl), —N(C1-6alkyl)2, C3-10cycloalkyl, 3-15 membered heterocyclyl, or —C(O)—C1-6alkoxy, wherein the C1-6alkyl of Rb is optionally substituted with one or more halo, —NH2, —NH(C1-6alkyl), —N(C1-6alkyl)2, —NH—C(O)C1-6alkyl, or —NH—C(O)—C1-6alkoxy, and the 3-15-membered heterocyclyl of Rb is optionally substituted with one or more halo or —C(O)—C1-6alkoxy.